Competitive AnalyticsCompetitive Research & AnalyticsCompetitive StrategyInsightInvestment OpportunityMarket Research & AnalysisMarket Research ServicesPharmaceuticalspharmaceuticals

Pharma CDMO – Market Attractiveness / Competitive Position Strategy

Industry Overview

In 2026, the global CDMO (Contract Development And Manufacturing Organization) industry has solidified its role as the "Backbone" of the pharmaceutical sector. No longer just a secondary outsourcing option, CDMOs are now essential strategic partners responsible for the majority of the world's drug manufacturing and technical innovation.

Competitive Landscape

Global top 10 Pharma CDMO in the market and their market share:

Company
Market Share

Lonza Group:
6.00%

Thermo Fisher:
4.50%

Catalent:
3.50%

Samsung Biologics:
3.00%

WuXi Biologics:
4.00%

Siefried:
1.00%

Fujifilm Diosynth Biotechnologies:
2.00%

Boehringer Ingelheim:
2.50%

Recipharm:
0.90%

MilliporeSigma:
0.80%

Global top 10 Pharma CDMO in the market and their market share

Market Segmentation

The Pharma CDMO major market segments: 

Small Molecules

Large Molecules/Biologics

Advanced Cell/Gene

Oral/Solid dose

Purity Players

Investment Potential

Our current market attractiveness analysis on Pharma CDMO reveals a strong and potential target market demand segments. 

The competitors are now focusing on advanced technology and advanced development model suggesting a shift in competitor technology transformation.

Recommendation

1. Competitors market attractiveness and competitive position

2. Your companys' market attractiveness and competitive position

3. Strategy for alternative position:

i. Target Market selection

ii. Strategy objectives

iii. Resource Allocation

 

Ready to get full report?